相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L. Hart et al.
ADVANCES IN THERAPY (2021)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2020)
Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs
Marco De Dominici et al.
BLOOD (2020)
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Beatriz Salvador-Barbero et al.
CANCER CELL (2020)
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
Scott F. Schoninger et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Requirement for epithelial p38α in KRAS-driven lung tumor progression
Jessica Vitos-Faleato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Ufuk Degirmenci et al.
CELLS (2020)
Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies
Marina N. Sharifi et al.
CANCER (2020)
The role of CDK6 in cancer
Sofie Nebenfuehr et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
CDK6 Inhibition: A Novel Approach in AML Management
Iris Z. Uras et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments
Angelina Pranteda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma
Ziyi Li et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2020)
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Jonathan W. Goldman et al.
FRONTIERS IN ONCOLOGY (2020)
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, invitro and in human tumor xenograft models
Fei Long et al.
CANCER SCIENCE (2019)
Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) plus binimetinib (BIM) plus cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Dual inhibition of MEK and p38 impairs tumor growth in KRAS-mutated non-small cell lung cancer
Noriaki Sunaga et al.
ONCOLOGY LETTERS (2019)
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12c inhibitor, in advanced solid tumors.
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
MONALEESA clinical program: a review of ribociclib use in different clinical settings
Denise A. Yardley
FUTURE ONCOLOGY (2019)
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
J. M. Weiss et al.
ANNALS OF ONCOLOGY (2019)
CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks
Iris Z. Uras et al.
BLOOD (2019)
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
Kai Zhang et al.
CANCER LETTERS (2019)
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
Keelan Z. Guiley et al.
SCIENCE (2019)
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
Marc Hafner et al.
CELL CHEMICAL BIOLOGY (2019)
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
S-H Chen et al.
ONCOGENE (2018)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan et al.
CANCER DISCOVERY (2018)
Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells
Begona Canovas et al.
CANCER CELL (2018)
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Renee de Leeuw et al.
CLINICAL CANCER RESEARCH (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells
Priyank Patel et al.
MOLECULAR CANCER RESEARCH (2018)
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
Florian Bellutti et al.
CANCER DISCOVERY (2018)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Shom Goel et al.
TRENDS IN CELL BIOLOGY (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
Gabriel N. Hortobagyi
BREAST CANCER RESEARCH (2018)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Cristina Guarducci et al.
NPJ BREAST CANCER (2018)
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Lori S. Hart et al.
CLINICAL CANCER RESEARCH (2017)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
Xin Li et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
Jiayuan Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
H. S. Kim et al.
ONCOGENE (2017)
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
Shenghui He et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant et al.
PLOS ONE (2017)
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong et al.
CANCER CELL (2017)
Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer
Jianya Zhou et al.
CANCER LETTERS (2017)
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P. B. Chapman et al.
ANNALS OF ONCOLOGY (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Eric Raspe et al.
EMBO MOLECULAR MEDICINE (2017)
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors
Birgit Geoerger et al.
CLINICAL CANCER RESEARCH (2017)
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Ana C. Garrido-Castro et al.
CURRENT BREAST CANCER REPORTS (2017)
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation
A-S Tigan et al.
ONCOGENE (2016)
Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
Iris Z. Uras et al.
BLOOD (2016)
Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells
Zhen Li et al.
CANCER LETTERS (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
Guowei Gu et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
John E. Bisi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
Michael S. Lee et al.
ONCOTARGET (2016)
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni et al.
ONCOTARGET (2016)
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
Mark A. Dickson et al.
JAMA ONCOLOGY (2016)
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Concepcion Sanchez-Martinez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
The Stress Kinase p38α as a Target for Cancer Therapy
Ana Igea et al.
CANCER RESEARCH (2015)
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)
Veronika Malinkova et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld et al.
NATURE GENETICS (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale et al.
SCIENCE SIGNALING (2015)
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale et al.
SCIENCE SIGNALING (2015)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele et al.
CLINICAL CANCER RESEARCH (2015)
c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard
Karoline Kollmann et al.
Oncotarget (2015)
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Theresa Placke et al.
BLOOD (2014)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3
Zhihong Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
Kathleen Keegan et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
Vipin Yadav et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
Jeffrey Alan Sosman et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Karoline Kollmann et al.
CANCER CELL (2013)
Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK
Lorena Pereira et al.
EMBO MOLECULAR MEDICINE (2013)
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
Kerstin Trunzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Targeting cell cycle and hormone receptor pathways in cancer
C. E. S. Comstock et al.
ONCOGENE (2013)
Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Maria R. Girotti et al.
CANCER DISCOVERY (2013)
CDK6 and p16INK4A in lymphoid malignancies
Karoline Kollmann et al.
ONCOTARGET (2013)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
Jeffry L. Dean et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM)
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N. Kwong et al.
NATURE MEDICINE (2012)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma
Salome Paillas et al.
CANCER RESEARCH (2011)
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Todd W. Miller et al.
CANCER DISCOVERY (2011)
Cyclin D as a therapeutic target in cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2011)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. H. T. Paraiso et al.
BRITISH JOURNAL OF CANCER (2010)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean et al.
ONCOGENE (2010)
EPIGENETICS AND GENETICS A census of amplified and overexpressed human cancer genes
Thomas Santarius et al.
NATURE REVIEWS CANCER (2010)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma
S. Nagel et al.
LEUKEMIA (2008)
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
Lisheng Wang et al.
BLOOD (2007)
Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation
Paloma Bragado et al.
APOPTOSIS (2007)
The pathways to tumor suppression via route p38
Jiahuai Han et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Differential regulation and properties of MAPKs
M. Raman et al.
ONCOGENE (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPα interaction
T. Fujimoto et al.
EMBO JOURNAL (2007)
p38α MAP kinase as a sensor of reactive oxygen species in tumorigenesis
Ignacio Dolado et al.
CANCER CELL (2007)
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses
Nick Giafis et al.
CANCER RESEARCH (2006)
Continuous ERK activation downregulates anti proliferative genes throughout G1 phase to allow cell-cycle progression
Takuya Yamamoto et al.
CURRENT BIOLOGY (2006)
Requirement for CDK4 kinase function in breast cancer
QY Yu et al.
CANCER CELL (2006)
Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells
B Nicke et al.
MOLECULAR CELL (2005)
Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
B Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
PL Toogood et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells
JTE Lim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a-p19Arf pathway
DV Bulavin et al.
NATURE GENETICS (2004)
Prognostic significance of phosphorylated p38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma
FJ Esteva et al.
CANCER (2004)
Stress-activated protein kinases - tumor suppressors or tumor initiators?
D Engelberg
SEMINARS IN CANCER BIOLOGY (2004)
Targeting the mitogen-activated protein kinase cascade to treat cancer
JS Sebolt-Leopold et al.
NATURE REVIEWS CANCER (2004)
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells
S Parmar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
AP-1: A double-edged sword in tumorigenesis
R Eferl et al.
NATURE REVIEWS CANCER (2003)
Map kinase signaling pathways and hematologic malignancies
LC Platanias
BLOOD (2003)
Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway
H Iwasa et al.
GENES TO CELLS (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
The retinoblastoma tumour suppressor in development and cancer
M Classon et al.
NATURE REVIEWS CANCER (2002)
The stress-activated protein kinases p38α and JNK1 stabilize p21Cip1 by phosphorylation
GY Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence
WP Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Transforming growth factor β1 induces proliferation in colon carcinoma cells by Ras-dependent, smad-independent down-regulation of p21cip1
ZF Yan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism
IM Pedersen et al.
BLOOD (2002)
Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress
M Benhar et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Specific protection against breast cancers by cyclin D1 ablation
QY Yu et al.
NATURE (2001)
Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase
DV Bulavin et al.
NATURE (2001)
分享论文
